Broadly Protective Anti-Viral Vaccines 2025

A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".

Deadline for manuscript submissions: 29 August 2025 | Viewed by 1213

Special Issue Editor


E-Mail Website
Guest Editor
Hunan Provincial Key Laboratory of Medical Virology, Institute of Pathogen Biology and Immunology of College of Biology, Hunan University, Changsha 410082, China
Interests: influenza virus; coronavirus; vaccinology; adaptive immunity; universal vaccine; antigen modification; cross-reactive antibody; antibody affinity maturation; B and T cell epitope; nanoparticle vaccine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to announce that the Special Issue “Broadly Protective Anti-viral Vaccines 2024” will open in March 2023. This Special Issue will accept original articles on the preventive and therapeutic anti-viral universal vaccine research, including but not limited to structural vaccinology, vaccine immunology, broadly-protective antibodies, T-cell epitope-based vaccines, vaccination regimens, vaccine genetics, vaccine production processes, vaccine pharmacology, vaccine adjuvants, and so on. The submissions of research articles, reviews, and commentary pieces are welcomed.

Vaccination is an effective and economical approach to control the spread of viral diseases. Emerging viruses could escape from vaccination-elicited prevailing herd immunity by antigenic mutations, thereafter vaccine efficacy often wanes over time. Seasonal influenza and SARS-CoV-2 are the most prominent representatives of rapidly evolving respiratory viruses. In addition, there are still no effective prophylactic or therapeutic vaccines that have been approved for human immunodeficiency virus, hepatitis C virus, and others. It necessitates the development of universal vaccines for conferring strong long-term cross-protection against these highly variable pathogens. In our Special Issue, we hope to include articles that will help us to address the relevant scientific questions.

Prof. Dr. Lei Deng
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • universal vaccines
  • structure-based rational design
  • cross-protection
  • broadly neutralizing antibody
  • T-cell epitopes
  • preventative and therapeutic vaccines
  • adaptive immunology
  • highly variable virus

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 2324 KiB  
Article
A Subunit Vaccine Harboring the Fusion Capsid Proteins of Porcine Circovirus Types 2, 3, and 4 Induces Protective Immune Responses in a Mouse Model
by Qikai Wang, Ran Zhang, Yue Wang, Ying Wang, Libin Liang, Haili Ma, Haidong Wang, Longlong Si and Xingchen Wu
Viruses 2024, 16(12), 1964; https://doi.org/10.3390/v16121964 - 23 Dec 2024
Viewed by 979
Abstract
Coinfections with porcine circovirus types 2, 3, and 4 (PCV2, PCV3, and PCV4) are increasingly being detected in the swine industry. However, there is no commercially available vaccine which prevents coinfection with PCV2, PCV3, and PCV4. The development of a vaccine expressing capsid [...] Read more.
Coinfections with porcine circovirus types 2, 3, and 4 (PCV2, PCV3, and PCV4) are increasingly being detected in the swine industry. However, there is no commercially available vaccine which prevents coinfection with PCV2, PCV3, and PCV4. The development of a vaccine expressing capsid (Cap) fusion proteins of multiple PCVs represents a promising approach for broadly preventing infection with PCVs. In this study, we developed a PCV subunit vaccine candidate (Cap 2-3-4) by predicting, screening, and fusing antigenic epitopes of Cap proteins of PCV2, PCV3, and PCV4. Immunoprotection assays showed that the prokaryotic expression of Cap 2-3-4 could effectively induce high levels of PCV2, PCV3, and PCV4 Cap-specific antibodies and successfully neutralize both PCV2 and PCV3. Furthermore, Cap 2-3-4 demonstrated a potent ability to activate cellular immunity and thus prevent lung damage in mice. This study provides a new option for the development of broad vaccines against PCVs. Full article
(This article belongs to the Special Issue Broadly Protective Anti-Viral Vaccines 2025)
Show Figures

Figure 1

Back to TopTop